This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in JAGSONPAL PHARMACEUTICALS LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
- AYOKI MERCANTILE LTD.
- ADVANCE LIFESTYLES LTD.
- RAMA PETROCHEMICALS LTD.
- GREYCELLS EDUCATION LIMITED
- RITES LIMITED
- JSW ISPAT SPECIAL PRODUCTS LIMITED
- IP RINGS LTD.
- USHA MARTIN LTD.
- DABUR INDIA LTD
- MISHKA EXIM LTD
- SHREE RAM URBAN INFRASTRUCTURE LTD.
- NINTEC SYSTEMS LIMITED
- ZYDUS WELLNESS LTD.
- WEST LEISURE RESORTS LTD
- SONA HI SONA JEWELLERS (GUJARAT) LIMITED
- DYNAMIC INDUSTRIES LTD.
- ASHNISHA INDUSTRIES LIMITED
- NUPUR RECYCLERS LIMITED
- SHREE GANESH FORGINGS LTD.
- KSOLVES INDIA LIMITED
Frequently Asked Questions
What is the Share price of JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM)?
Can I buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares?
How do I buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) from Angel One?
- Direct investment: You can buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares.
In which sector do JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) belong?
Today's live share price for JAGSONPAL PHARMACEUTICALS LTD. is NSE: ₹ 345.65, BSE: ₹ 345.00 with a current market capitalization of .
Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.Read more